Safety, efficacy & recurrence rates of imiquimod cream 5% for treatment of anogenital warts.
Imiquimod 5% cream (Aldara, Graceway Pharmaceuticals) is an immune response modifier used for the topical treatment of anogenital warts in non-HIV-infected patients. Several randomized controlled trials have demonstrated that imiquimod 5% cream is a safe and efficacious treatment. Current data regarding efficacy shows that complete clearance of warts occurred in up to 50% of patients treated with imiquimod 5% cream applied once-daily, 3 times per week for up to 16 weeks. Recurrence rates ranged from up to 19% at 3 months to 23% at 6 months. Imiquimod 5% cream showed an acceptable safety profile; local inflammatory reactions were the most frequent adverse effects, with local erythema being the most common.
Diamantis
M L
ML
The University of Texas Medical School at Houston, Houston, TX, USA.
Bartlett
B L
BL
Tyring
S K
SK
D000279:Administration, Cutaneous; D000634:Aminoquinolines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001004:Anus Diseases / Q000188:drug therapy / Q000601:surgery / Q000821:virology; D003131:Combined Modality Therapy; D003218:Condylomata Acuminata / Q000188:drug therapy* / Q000601:surgery / Q000821:virology; D005260:Female; D006801:Humans; D000077271:Imiquimod; D007369:Interferon Inducers / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D055502:Secondary Prevention
D000634:Aminoquinolines; D007369:Interferon Inducers; D000077271:Imiquimod